Budapest‑based Turbine raised $25 million in a Series B round to accelerate commercialization of its 'Virtual Lab' platform—AI models that simulate cellular behavior for drug discovery and lead optimization. The company, operating for over a decade, plans to sell its virtual cell simulation tools to pharmaceutical partners to shorten early‑stage development timelines. Virtual cells are computational models that predict cellular responses to perturbations; one‑sentence clarification: these systems emulate intracellular pathways and phenotypes to prioritize compounds before wet‑lab testing. Turbine’s raise signals continuing investor interest in in‑silico biology as an efficiency lever for pharma R&D.